Compound Evidence File
#EC-2026-0670
Lipo-C FAT BLASTER
Filed under Injectable Oils. The bureau holds 106 laboratory returns for this compound from 38 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
38 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 10.0 | 9.9 | 10.0 | 20 Feb 2026 | 8 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 9.9 | 10.0 | 12 Feb 2026 | 2 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 9.9 | 10.0 | 23 Nov 2025 | 24 May 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 27 Dec 2025 | 26 Apr 2026 |
| Yabang PeptideCASE #VI-2026-0148 | X | 1 | 10.0 | 10.0 | 10.0 | 6 May 2025 | 6 May 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Dec 2025 | 26 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 7 Apr 2026 | 24 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 21 Feb 2026 | 24 May 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 9.9 | 8 Mar 2026 | 6 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 9.9 | 9.9 | 10.0 | 3 May 2026 | 17 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 10 May 2026 | 10 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 19 Apr 2026 | 26 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 10.0 | 13 Mar 2026 | 11 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 9.9 | 17 Jan 2026 | 25 Apr 2026 |
| HkRoidsCASE #VI-2026-0784 | X | 1 | 9.5 | 9.5 | 9.5 | 13 Feb 2025 | 13 Feb 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 3 | 9.2 | 8.9 | 9.6 | 25 May 2026 | 25 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 8.6 | 7.9 | 9.2 | 25 May 2026 | 25 May 2026 |
| LipeptidesCASE #VI-2026-0863 | X | 1 | 8.6 | 8.6 | 8.6 | 6 May 2025 | 6 May 2025 |
| Shanghai Wibson Biotechnology WBSCASE #VI-2026-0214 | X | 1 | 8.5 | 8.5 | 8.5 | 20 Jun 2025 | 20 Jun 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 3 | 8.4 | 7.7 | 9.1 | 23 May 2026 | 23 May 2026 |
| Eros PeptidesCASE #VI-2026-0918 | X | 1 | 8.4 | 8.4 | 8.4 | 27 Feb 2025 | 27 Feb 2025 |
| OmegAminoCASE #VI-2026-0014 | X | 1 | 8.3 | 8.3 | 8.3 | 3 Jul 2025 | 3 Jul 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.2 | 7.0 | 9.7 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 8.2 | 6.0 | 10.0 | 24 May 2026 | 24 May 2026 |
| Evolve BioPepCASE #VI-2026-0755 | X | 1 | 8.0 | 8.0 | 8.0 | 27 Feb 2025 | 27 Feb 2025 |
| Kits4lessCASE #VI-2026-0744 | X | 1 | 7.7 | 7.7 | 7.7 | 28 Mar 2025 | 28 Mar 2025 |
| HK PeptidesCASE #VI-2026-0140 | X | 8 | 7.4 | 5.2 | 10.0 | 14 Jan 2025 | 25 May 2026 |
| Nuscience PeptidesCASE #VI-2026-0554 | X | 3 | 7.3 | 6.5 | 8.6 | 11 Jun 2025 | 23 May 2026 |
| Peptide PartnersCASE #VI-2026-0295 | X | 5 | 7.2 | 5.2 | 8.8 | 3 Jul 2025 | 21 May 2026 |
| PeptidologyCASE #VI-2026-0520 | X | 1 | 7.1 | 7.1 | 7.1 | 9 Jun 2025 | 9 Jun 2025 |
| Alpha-GenCASE #VI-2026-0905 | X | 1 | 6.7 | 6.7 | 6.7 | 7 May 2025 | 7 May 2025 |
| Zhejiang Yichenkang BiotechnologyCASE #VI-2026-0269 | X | 4 | 6.6 | 5.5 | 8.2 | 8 Jul 2025 | 21 May 2026 |
| Top PeptideCASE #VI-2026-0721 | X | 2 | 6.6 | 5.7 | 7.4 | 28 Mar 2025 | 26 Jan 2026 |
| PurePEPSCASE #VI-2026-0552 | X | 1 | 6.6 | 6.6 | 6.6 | 20 Jun 2025 | 20 Jun 2025 |
| Bio PepzCASE #VI-2026-0436 | X | 1 | 5.8 | 5.8 | 5.8 | 21 May 2025 | 21 May 2025 |
| Marvel PeptideCASE #VI-2026-0507 | X | 1 | 2.4 | 2.4 | 2.4 | 28 Mar 2025 | 28 Mar 2025 |
Open any subject to view the batch-level evidence for Lipo-C FAT BLASTER alone.